Guardion’s Lumega-Z Formula Associated with Substantial Clinical Improvement in Patients Contrast Sensitivity Visual Functi...
May 09 2019 - 9:14AM
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(Nasdaq: GHSI), an ocular health sciences and technologies company
that develops, formulates and distributes condition-specific
medical foods and testing technologies supported by evidence-based
protocols, today announced the results of a study from research
scientists at the Western University College of Optometry to
clinically evaluate the visual benefits of the Company’s micronized
liquid formula Lumega-Z as compared to the AREDS 2 softgel
supplement in individuals with retinal drusen and at risk of
developing Age-Related Macular Degeneration (AMD).
Dr. David Evans, Ph.D., Guardion’s Chief Science
Officer, commenting on the results of the study, stated, “We are
pleased to present for the first-time clinical data showing the
beneficial effects of our liquid lipid-based formula Lumega-Z as
compared to the AREDS 2 softgel supplement. This data supports
numerous clinical reports that we have showing substantial clinical
improvements in patients who switched from the AREDS 2 softgel to
Lumega-Z. This data also extends the important work conducted by
the National Eye Institute emphasizing the importance of
nutritional therapy in combating the growing epidemic of vision
loss from Age-Related Macular Degeneration.”
Information and risk factors with respect to
Guardion and its business, including its ability to successfully
develop and commercialize its proprietary products and
technologies, may be obtained in the Company’s filings with the
Securities and Exchange Commission (“SEC”) at www.sec.gov.
About Guardion Health Sciences,
Inc.
Guardion is an ocular health sciences company
that develops, formulates and distributes condition-specific
medical foods supported by evidence-based protocols, with an
initial medical food product, Lumega-Z, that addresses a depleted
macular protective pigment, a known risk factor for age-related
macular degeneration (“AMD”) and a significant component of
functional vision performance. Guardion Health Sciences, Inc. has
also developed a proprietary medical device, the MapcatSF®, which
accurately measures the macular pigment density, therefore
providing the only two-pronged evidence-based protocol for the
treatment of a depleted macular protective pigment.
About
VectorVision®
VectorVision®, operating through a wholly-owned
subsidiary of the Company, specializes in the standardization of
contrast sensitivity, glare sensitivity, low contrast acuity, and
ETDRS acuity vision testing. Its patented standardization system
provides the practitioner or researcher the ability to delineate
very small changes in visual capability, either as compared to the
population or from visit to visit. VectorVision®’s CSV-1000 device
is considered the standard of care for clinical trials.
Forward-Looking Statement
Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. These statements
involve unknown risks and uncertainties that may individually or
materially impact the matters discussed herein for a variety of
reasons that are outside the control of the Company, including, but
not limited to, the Company’s ability to raise sufficient financing
to implement its business plan and its ability to successfully
develop and commercialize its proprietary products and
technologies. Readers are cautioned not to place undue reliance on
these forward-looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s filings with the SEC, which are available at
the SEC’s website (www.sec.gov). The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Company
Contact:
Investor Relations Contact:Michael
Favish
Matthew AbenanteChief Executive
Officer
Porter, LeVay & Rose, Inc. Telephone: (858) 605-9055 x
201
Telephone: (212) 564-4700
E-mail:
mfavish@guardionhealth.com
E-mail: matthew@plrinvest.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Apr 2024 to May 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From May 2023 to May 2024